Departments of Medicine.
Surgery.
J Clin Gastroenterol. 2023 Jul 1;57(6):537-545. doi: 10.1097/MCG.0000000000001852.
Alcohol-associated liver disease has seen a significant rise in the last 2 decades, with an associated rise in the need for accurate alcohol use assessment. Alcohol use has been associated with poor outcomes in both the pre-liver transplant and post-liver transplant patients. Patients with alcohol use disorder often under-report their alcohol consumption because of varying factors, highlighting the need for objective assessment of alcohol use. Aside from the available self-report questionnaires, multiple serologic biomarkers are currently available to assist clinicians to assess recent alcohol consumption among patients with chronic liver disease, liver transplant candidates, and recipients. In this review, we will assess some of these alcohol biomarkers, discuss their strengths and weakness, and review-available data to discuss their role in pre-liver transplant and post-liver transplant population.
在过去的 20 年中,与酒精相关的肝脏疾病显著增加,因此对准确评估酒精使用情况的需求也相应增加。酒精使用与肝移植前和肝移植后患者的不良预后都有关。由于各种因素的影响,患有酒精使用障碍的患者常常会少报自己的饮酒量,这凸显出需要对酒精使用情况进行客观评估。除了现有的自我报告问卷外,目前还有多种血清生物标志物可帮助临床医生评估慢性肝病、肝移植候选者和受者的近期饮酒情况。在这篇综述中,我们将评估其中一些酒精生物标志物,讨论它们的优缺点,并回顾现有数据以讨论它们在肝移植前和肝移植后人群中的作用。